Loss of androgen receptor (AR) signaling dependence occurs in approximately 15%–20%
of advanced treatment-resistant prostate cancers, and this may manifest clinically as …

Proteolysis targeting chimera (PROTAC) is an emerging pharmacological modality with
innovated post‐translational protein degradation capabilities. However, off‐target induced …

Prostate cancer is a major cause of cancer morbidity and mortality. Intra-prostatic
inflammation is a risk factor for prostate carcinogenesis, with diet, chemical injury and an …

Prostate cancer is among most malignant tumors around the world and this urological tumor
can be developed as result of genomic mutations and their accumulation during progression …

Abstract c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression.
Although MYC is overexpressed in both early and metastatic disease and associated with …

Most tumors exhibit intra-tumor heterogeneity, which is associated with disease progression
and an impaired response to therapy. Cancer cell plasticity has been proposed as being an …

The incidence of aggressive neuroendocrine prostate cancers (NEPC) related to androgen-
deprivation therapy (ADT) is rising. NEPC is still poorly understood, such as its …

Systemic therapy often results in the reduction of tumor size but rarely succeeds in
eradicating all cancer cells. Drug efflux, persistence of cancer stem cells (CSCs), epithelial …

Combining immune checkpoint therapy (ICT) and targeted therapy holds great promises for
broad and long-lasting anti-cancer therapies. However, combining ICT with anti-PI3K …

Prostate organogenesis is a complex process that is primarily mediated by the presence of
androgens and subsequent mesenchyme-epithelial interactions. The investigation of …